Tpl2 inhibitors thwart endothelial cell function in angiogenesis and peritoneal dissemination

Neoplasia (United States)

Volumn 15, Issue 9, 2013, Pages 1036-1048

  Lee, Wen Jane ^a,b   Lan, Keng Hsin ^c,d   Chou, Chiang Ting ^e   Yi, Yu Chiao ^a   Chen, Wei Chih ^a   Pan, Hung Chuan ^a,d   Peng, Yen Chun ^a   Wang, Keh Bin ^f   Chen, Yi Ching ^f   Chao, Te Hsin ^a   Tien, Hsing Ru ^g   Sheu, Wayne Huey Herng ^a,g   Sheu, Meei Ling ^a,g  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b TUNGHAI UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^f KUANG TIEN GENERAL HOSPITAL   (Taiwan)

^g NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING PROTEIN 1; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; CCAAT ENHANCER BINDING PROTEIN BETA; CD31 ANTIGEN; CXCL1 CHEMOKINE; CYCLINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; PHOSPHOTRANSFERASE; PROTEIN TUMOR PROGRESSION LOCUS 2; PROTEIN TUMOR PROGRESSION LOCUS 2 INHIBITOR; PROTEIN TUMOR PROGRESSION LOCUS 2 KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; GENETIC TRANSCRIPTION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ACTIVATING TRANSCRIPTION FACTOR 1; ANIMALS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CXCL1; ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MAP KINASE KINASE KINASES; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884367181     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121914     Document Type: Article

References (62)

1. Risco A, del Fresno FC, Mambol A, Alsina-Beauchamp D, MacKenzie KF, Yang HT, Barber DF, Morcelle C, Arthur JS, Ley SC, et al. (2012). p38γ and p38δ kinases regulate the Toll-like receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation. Proc Natl Acad Sci USA 109, 11200-11205.
2. Mielke LA, Elkins KL, Wei L, Starr R, Tsichlis PN, O'Shea JJ, and Watford WT (2009). Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1β production. J Immunol 183, 7984-7993.
3. 290 is induced by lipopolysaccharide via an Iκ-B kinase-β-dependent pathway and is required for Tpl2 activation by external signals. J Biol Chem 280, 20442-20448.
4. Watford WT, Wang CC, Tsatsanis C, Mielke LA, Eliopoulos AG, Daskalakis C, Charles N, Odom S, Rivera J, O'Shea J, et al. (2010). Ablation of tumor progression locus 2 promotes a type 2 Th cell response in ovalbumin-immunized mice. J Immunol 184, 105-113.
5. Christoforidou AV, Papadaki HA, Margioris AN, Eliopoulos GD, and Tsatsanis C (2004). Expression of the Tpl2/Cot oncogene in human T-cell neoplasias. Mol Cancer 3, 34.
6. Krcova Z, Ehrmann J, Krejci V, Eliopoulos A, and Kolar Z (2008). Tpl-2/Cot and COX-2 in breast cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 152, 21-25.
7. Sourvinos G, Tsatsanis C, and Spandidos DA (1999). Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene 18, 4968-4973.
8. Ohara R, Hirota S, Onoue H, Nomura S, Kitamura Y, and Toyoshima K (1995). Identification of the cells expressing cot proto-oncogene mRNA. J Cell Sci 108(Pt 1), 97-103.
9. Hatziapostolou M, Polytarchou C, Panutsopulos D, Covic L, and Tsichlis PN (2008). Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration. Cancer Res 68, 1851-1861.
10. Jeong JH, Bhatia A, Toth Z, Oh S, Inn KS, Liao CP, Roy-Burman P, Melamed J, Coetzee GA, and Jung JU (2011). TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth. PLoS One 6, e16205.
11. Lee KM, Lee KW, Bode AM, Lee HJ, and Dong Z (2009). Tpl2 is a key mediator of arsenite-induced signal transduction. Cancer Res 69, 8043-8049.
12. Brower V (2009). How well do angiogenesis inhibitors work? Biomarkers of response prove elusive. J Natl Cancer Inst 101, 846-847.
13. Hussain S, Slevin M, Matou S, Ahmed N, Choudhary MI, Ranjit R, West D, and Gaffney J (2008). Anti-angiogenic activity of sesterterpenes; natural product inhibitors of FGF-2-induced angiogenesis. Angiogenesis 11, 245-256.
14. Cao R, Ji H, Feng N, Zhang Y, Yang X, Andersson P, Sun Y, Tritsaris K, Hansen AJ, Dissing S, et al. (2012). Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci USA 109, 15894-15899.
15. Komuro A, Yashiro M, Iwata C, Morishita Y, Johansson E, Matsumoto Y, Watanabe A, Aburatani H, Miyoshi H, Kiyono K, et al. (2009). Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor β signaling. J Natl Cancer Inst 101, 592-604.
16. Warner KA, Miyazawa M, Cordeiro MM, Love WJ, Pinsky MS, Neiva KG, Spalding AC, and Nor JE (2008). Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. Neoplasia 10, 131-139.
17. Tan DS, Agarwal R, and Kaye SB (2006). Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 7, 925-934.
18. Liu SH, Wang KB, Lan KH, Lee WJ, Pan HC, Wu SM, Peng YC, Chen YC, Shen CC, Cheng HC, et al. (2012). Calpain/SHP-1 interaction by Honokiol dampening peritoneal dissemination of gastric cancer in nu/nu mice. PLoS One 7, e43711.
19. Malz M, Weber A, Singer S, Riehmer V, Bissinger M, Riener MO, Longerich T, Soll C, Vogel A, Angel P, et al. (2009). Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. Hepatology 50, 1130-1139.
20. Schulz P, Fischer C, Detjen KM, Rieke S, Hilfenhaus G, von MZ, Bohmig M, Koch I, Kehrberger J, Hauff P, et al. (2011). Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer. FASEB J 25, 3325-3335.
21. Akino T, Hida K, Hida Y, Tsuchiya K, Freedman D, Muraki C, Ohga N, Matsuda K, Akiyama K, Harabayashi T, et al. (2009). Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 175, 2657-2667.
22. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, and Klagsbrun M (2004). Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 64, 8249-8255.
23. Tchaicha JH, Mobley AK, Hossain MG, Aldape KD, and McCarty JH (2010). A mosaic mouse model of astrocytoma identifies αvβ8 integrin as a negative regulator of tumor angiogenesis. Oncogene 29, 4460-4472.
24. Darnell JE Jr. (2002). Transcription factors as targets for cancer therapy. Nat Rev Cancer 2, 740-749.
25. Niu J, Chang Z, Peng B, Xia Q, Lu W, Huang P, Tsao MS, and Chiao PJ (2007). Keratinocyte growth factor/fibroblast growth factor-7-regulated cell migration and invasion through activation of NF-κB transcription factors. J Biol Chem 282, 6001-6011.
26. Royds JA, Dower SK, Qwarnstrom EE, and Lewis CE (1998). Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Pathol 51, 55-61.
27. Watari K, Nakamura M, Fukunaga Y, Furuno A, Shibata T, Kawahara A, Hosoi F, Kuwano T, Kuwano M, and Ono M (2012). The antitumor effect of a novel angiogenesis inhibitor (an octahydronaphthalene derivative) targeting both VEGF receptor and NF-κB pathway. Int J Cancer 131, 310-321.
28. Chun KS, Kundu JK, Park KK, Chung WY, and Surh YJ (2006). Inhibition of phorbol ester-induced mouse skin tumor promotion and COX-2 expression by celecoxib: C/EBP as a potential molecular target. Cancer Res Treat 38, 152-158.
29. Kagan BL, Henke RT, Cabal-Manzano R, Stoica GE, Nguyen Q, Wellstein A, and Riegel AT (2003). Complex regulation of the fibroblast growth factorbinding protein in MDA-MB-468 breast cancer cells by CCAAT/enhancerbinding protein β. Cancer Res 63, 1696-1705.
30. Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, et al. (2006). The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 9, 209-223.
31. Wood LD, Farmer AA, and Richmond A (1995). HMGI(Y) and Sp1 in addition to NF-κB regulate transcription of the MGSA/GRO α gene. Nucleic Acids Res 23, 4210-4219.
32. Luan J, Shattuck-Brandt R, Haghnegahdar H, Owen JD, Strieter R, Burdick M, Nirodi C, Beauchamp D, Johnson KN, and Richmond A (1997). Mechanism and biological significance of constitutive expression of MGSA/ GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol 62, 588-597.
33. Amiri KI, Ha HC, Smulson ME, and Richmond A (2006). Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADPribose) polymerase-1. Oncogene 25, 7714-7722.
34. Nirodi C, NagDas S, Gygi SP, Olson G, Aebersold R, and Richmond A (2001). A role for poly(ADP-ribose) polymerase in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression. J Biol Chem 276, 9366-9374.
35. Yang J, McNeish B, Butterfield C, and Moses MA (2012). Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J 27, 45-50.
36. Liu SH, Sheu WH, Lee MR, Lee WJ, Yi YC, Yang TJ, Jen JF, Pan HC, Shen CC, Chen WB, et al. (2012). Advanced glycation end product N e{open} carboxymethyllysine induces endothelial cell injury: the involvement of SHP-1regulated VEGFR-2 dephosphorylation. J Pathol 230, 215-227.
37. Liu SH, Yang CN, Pan HC, Sung YJ, Liao KK, Chen WB, Lin WZ, and Sheu ML (2010). IL-13 downregulates PPAR-γ/heme oxygenase-1 via ER stressstimulated calpain activation: aggravation of activated microglia death. Cell Mol Life Sci 67, 1465-1476.
38. Aoyagi K, Kouhuji K, Yano S, Miyagi M, Imaizumi T, Takeda J, and Shirouzu K (2005). VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer 8, 155-163.
39. Liu Y, Han ZP, Zhang SS, Jing YY, Bu XX, Wang CY, Sun K, Jiang GC, Zhao X, Li R, et al. (2011). Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. J Biol Chem 286, 25007-25015.
40. Klauber-Demore N (2012). Are epsins a therapeutic target for tumor angiogenesis? J Clin Invest 122, 4341-4343.
41. Kerbel RS (2000). Tumor angiogenesis: past, present and the near future. Carcinogenesis 21, 505-515.
42. Ribatti D (2011). Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway. Cancer Treat Rev 37, 344-352.
43. Butler JM, Kobayashi H, and Rafii S (2010). Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 10, 138-146.
44. Bonavia R, Inda MM, Vandenberg S, Cheng SY, Nagane M, Hadwiger P, Tan P, Sah DW, Cavenee WK, and Furnari FB (2012). EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene 31, 4054-4066.
45. Bobrovnikova-Marjon EV, Marjon PL, Barbash O, Vander Jagt DL, and Abcouwer SF (2004). Expression of angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: role of nuclear factor-κB and activating protein-1. Cancer Res 64, 4858-4869.
46. Kishimoto K, Liu S, Tsuji T, Olson KA, and Hu GF (2005). Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 24, 445-456.
47. Dong W, Li Y, Gao M, Hu M, Li X, Mai S, Guo N, Yuan S, and Song L (2012). IKKα contributes to UVB-induced VEGF expression by regulating AP-1 transactivation. Nucleic Acids Res 40, 2940-2955.
48. Hirata K, Taki H, Shinoda K, Hounoki H, Miyahara T, Tobe K, Ogawa H, Mori H, and Sugiyama E (2010). Inhibition of tumor progression locus 2 protein kinase suppresses receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis through down-regulation of the c-Fos and nuclear factor of activated T cells c1 genes. Biol Pharm Bull 33, 133-137.
49. Watford WT, Hissong BD, Durant LR, Yamane H, Muul LM, Kanno Y, Tato CM, Ramos HL, Berger AE, Mielke L, et al. (2008). Tpl2 kinase regulates T cell interferon-γ production and host resistance to Toxoplasma gondii. J Exp Med 205, 2803-2812.
50. cicco-Skinner KL, Trovato EL, Simmons JK, Lepage PK, and Wiest JS (2011). Loss of tumor progression locus 2 (tpl2) enhances tumorigenesis and inflammation in two-stage skin carcinogenesis. Oncogene 30, 389-397.
51. min mice by inhibiting IL-10 secretion and regulatory T-cell generation. Proc Natl Acad Sci USA 109, E1082-E1091.
52. Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH, Patriotis C, Jenkins NA, Copeland NG, Kollias G, et al. (2000). TNF-α induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103, 1071-1083.
53. Gantke T, Sriskantharajah S, and Ley SC (2011). Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase. Cell Res 21, 131-145.
54. Li X, Feng J, Chen S, Peng L, He WW, Qi J, Deng H, and Sun R (2010). Tpl2/AP-1 enhances murine gammaherpesvirus 68 lytic replication. J Virol 84, 1881-1890.
55. Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E, Repici A, Sturm A, Malesci A, Panes J, et al. (2009). VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 136, 585-595.
56. Walsh DA and Pearson CI (2001). Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res 3, 147-153.
57. Imhof BA and Aurrand-Lions M (2006). Angiogenesis and inflammation face off. Nat Med 12, 171-172.
58. Jackson JR, Seed MP, Kircher CH, Willoughby DA, and Winkler JD (1997). The codependence of angiogenesis and chronic inflammation. FASEB J 11, 457-465.
59. Zhang SQ, Yu H, and Zhang LL (2009). Clinical implications of increased lymph vessel density in the lymphatic metastasis of early-stage invasive cervical carcinoma: a clinical immunohistochemical method study. BMC Cancer 9, 64.
60. Coşkun U, Akyürek N, Dursun A, and Yamaç D (2010). Peritumoral lymphatic microvessel density associated with tumor progression and poor prognosis in gastric carcinoma. J Surg Res 164, 110-115.
61. Gao J, Knutsen A, Arbman G, Carstensen J, Franlund B, and Sun XF (2009). Clinical and biological significance of angiogenesis and lymphangiogenesis in colorectal cancer. Dig Liver Dis 41, 116-122.
62. Gao P, Zhou GY, Zhang QH, Xiang L, Zhang SL, Li C, and Sun YL (2008). Clinicopathological significance of peritumoral lymphatic vessel density in gastric carcinoma. Cancer Lett 263, 223-230.